| Name | Title | Contact Details |
|---|
BioPorto s flagship product, The NGAL Test™, aids in the risk assessment of AKI in critically ill patients. CE marked for IVD use in select regions.
TCR² Therapeutics Inc. is a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer. TCR²`s proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while exhibiting lower levels of cytokine release.
Phosplatin Therapeutics is a private, clinical stage biopharmaceutical company founded in 2010, and funded by private investors and family investment offices in the U.S., Europe and Asia.
Taueret Laboratories is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Glow Skin Care Studio is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.